| Aklief (trifarotene) / Galderma |
2020-006050-51: To determine if trifarotene (commercially known at Aklief) has anadditional risk of acne scar formation compared to a vehicle cream (creamwithout an active ingredient). This study will be completed for 24 weeks. Déterminer si le trifarotène (connu dans le commerce chez Aklief) présenteun risque supplémentaire de formation de cicatrices d'acné par rapport àune crème véhicule (crème sans ingrédient actif). Cette étude seracomplétée pendant 24 semaines. |
|
|
| Not yet recruiting | 4 | 118 | Europe | trifarotene, AKLIEF 50 microgrammes/g crème, Cream, Aklief (trifarotene 50 μg/g cream) | Galderma S.A., Galderma S.A | acne vulgaris Acné vulgaire, Acne Acne, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2021-003608-41: AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation (LEAP) EvaLuación de AkliEf en la hiperpigmentAción Postinflamatoria inducida por el acné (LEAP) |
|
|
| Not yet recruiting | 4 | 120 | Europe | Trifarotene, AKLIEF 50 microgramos/g crema, Cream, Aklief (trifarotene 50 µg/g cream) | Galderma S.A., Galderma S.A. | Moderate acne vulgaris with acne-induced post-inflammatory hyperpigmentation (PIH) Acné vulgar moderado con hiperpigmentación postinflamatoria, Moderate facial acne vulgaris Acné vulgar facial moderado, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
| Completed | 4 | 121 | Europe, Canada, US | Trifarotene Cream, AKLIEF®, Trifarotene Vehicle Cream | Galderma R&D | Acne Vulgaris | 02/23 | 06/23 | | |
NCT05550337: Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris |
|
|
| Completed | 3 | 807 | US | Trifarotene 0.005 % Topical Cream, AKLIEF®, Placebo, Vehicle of Test Product | Teva Pharmaceuticals USA, Teva Pharmaceuticals, Inc. | Acne Vulgaris | 05/23 | 05/23 | | |
2008-007981-44: EXPLORATORY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CD5789 IN SUBJECTS WITH ACNE |
|
|
| Ongoing | 2 | 70 | Europe | CD5789, Epiduo, CD5789, CD271/CD1579, Epiduo®, Epiduo® | GALDERMA R&D SNC | Acne vulgaris | | | | |
NCT06063473: A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris |
|
|
| Completed | 1 | 762 | US | Trifarotene Cream 0.005%, Test Product, Placebo, Vehicle, AKLIEF® Cream (Trifarotene 0.005%, Galderma Laboratories), Reference Product | Taro Pharmaceuticals USA | Acne Vulgaris | 07/23 | 07/23 | | |
NCT06733402: A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris |
|
|
| Completed | 1 | 1000 | US | Trifarotene Cream 0.005%, Test Product, AKLIEF® Cream (Trifarotene 0.005%) US REFERENCE LISTED DRUG, Reference Product, AKLIEF® Cream (Trifarotene 50 mcg/g) CANADIAN REFERENCE PRODUCT, Placebo, Vehicle | Taro Pharmaceuticals USA | Acne Vulgaris | 06/24 | 11/24 | | |
